Search Results 1071-1080 of 17010 for monoclonal antibody

  1. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

    Treatment with commercially available or investigational large molecule cancer therapies, including monoclonal antibodies (mAbs), bispecific antibodies, ...

  2. Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn's Disease - Mayo Clinic

    Treatment with any monoclonal antibody within 4 weeks of screening; History or evidence of colonic mucosal dysplasia; HIV, hepatitis B, hepatitis C, or ...

  3. A Study of the Safety and Effectiveness of GS-5745 in Participants with Moderately to Severely Active Crohn's Disease - Mayo Clinic

    Treatment with any monoclonal antibody within 4 weeks of screening; History or evidence of colonic mucosal dysplasia; HIV, hepatitis B, hepatitis C, or ...

  4. A Study of the Safety and Effectiveness of Combined Copaxone and Estriol for Relapsing Remitting Multiple Sclerosis - Mayo Clinic

    Monoclonal antibody; T cell vaccination; Cladribine; Bone marrow transplantation; Azathioprine; Cyclophosphamide; Methotrexate; Mitoxantrone; Cyclosporin ...

  5. A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma - Mayo Clinic

    Monoclonal antibody, at least 3 half-lives from last dose;; Non-antibody immunotherapy (e.g., tumor vaccine), at least 42 days from last dose ...

  6. Mayo Clinic Minute: How the immune system can make getting an organ transplant trickier

    Bentall says. He says it happens when a person has antibodies that cause their immune system to reject a transplanted organ. "The immune system doesn't ...

  7. A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFNβ-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors - Mayo Clinic

    Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: ≤4 weeks (≤3 weeks with documented disease ...

  8. Myeloma Referral Study (Race, Ethnicity, and Familial Etiologic Relationship, Risk Association, and Linkage Study) - Mayo Clinic

    About this study. The goal of the present study is to answer the question of whether there are clinically relevant subtypes of monoclonal gammopathy of ...

  9. Publications - Nadine H. Abdallah, M.D. - Mayo Clinic

    Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression. Leukemia. 2025 May; 39 (5): ...

  10. A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis - Mayo Clinic

    Participation eligibility · History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the ...